Currently, Tolvaptan, a highly selective antagonist at the V2 vasopressin receptor (AVP), is a specific therapy approved for the treatment of ADPKD; it has been demonstrated that Tolvaptan reduces the growth rate of cysts and slows the increase in TKV, slowing ESKD. This evidence concerns the gene AVP and autosomal dominant polycystic kidney disease.